{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:16:56Z","timestamp":1790806616958,"version":"4.1.0"},"reference-count":20,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,8,11]]},"DOI":"10.18632\/oncotarget.27695","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T15:10:02Z","timestamp":1597158602000},"page":"3061-3068","source":"Crossref","is-referenced-by-count":18,"title":["Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients"],"prefix":"10.18632","volume":"11","author":[{"given":"Aman","family":"Chauhan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine-Medical Oncology and the Markey Cancer Center, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham","family":"El-Khouli","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Waits","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohitashva","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Medical Oncology and the Markey Cancer Center, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariha","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Tarter","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millicent","family":"Horn","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and the Markey Cancer Center, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Oates","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Mark","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Surgery and the Markey Cancer Center, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell","family":"Anthony","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Medical Oncology and the Markey Cancer Center, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11154-017-9429-9","article-title":"Management of pulmonary neuroendocrine tumors","volume":"1","author":"Voros","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"2","first-page":"755","article-title":"Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid Syndrome","volume":"2","author":"Anthony","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.annpat.2017.10.003","article-title":"[Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future]","volume":"3","author":"R\u00e9seau","year":"2017","journal-title":"Ann Pathol"},{"key":"4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.2017-0364","article-title":"Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)","volume":"2","author":"Beguiristain","year":"2018","journal-title":"Oncologist"},{"key":"5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis formultireceptor tumour targeting","volume":"3","author":"Waser","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5603\/NMR.2011.0004","article-title":"The diagnostic role of 68Ga-DOTATATE PET\/CT in the detection of neuroendocrine tumours","volume":"1","author":"Sackiewicz-Slaby","year":"2011","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"7","first-page":"426","article-title":"The value of (68)Ga-DOTATATE PET\/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature","volume":"4","author":"Delpassand","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial ofLu-Dotatate for Midgut Neuroendocrine Tumors","volume":"37","author":"Baum","year":"2017","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"5","author":"Bomanji","year":"2010","journal-title":"J Nucl Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2967\/jnumed.111.101675","article-title":"The role of 68Ga-DOTATATE PET\/CT in suspected neuroendocrine tumors","volume":"5","author":"Hacker","year":"2012","journal-title":"J Nucl Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2967\/jnumed.110.084236","article-title":"Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment","volume":"5","author":"Reubi","year":"2011","journal-title":"J Nucl Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12149-014-0898-6","article-title":"68Gallium- and 90Yttrium-\/177Lutetium: \u201ctheranostic twins\u201d for diagnosis and treatment of NETs","volume":"2","author":"Herrmann","year":"2015","journal-title":"Ann Nucl Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.114.148247","article-title":"Impact of 68Ga-DOTATATE PET\/CT on the management of neuroendocrine tumors: the referring physician\u2019s perspective","volume":"5","author":"Allen-Auerbach","year":"2015","journal-title":"J Nucl Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.117.192450","article-title":"Most of the Intended Management Changes After (68)Ga-DOTATATE PET\/CT Are Implemented","volume":"5","author":"Quon","year":"2017","journal-title":"J Nucl Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"2","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective Study of 68Ga-DOTATATE Positron Emission Tomography\/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites","volume":"3","author":"Kebebew","year":"2016","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.2967\/jnumed.116.180984","article-title":"Localization of Unknown Primary Site with (68)Ga-DOTATOC PET\/CT in Patients with Metastatic Neuroendocrine Tumor","volume":"5","author":"O\u2019Dorisio","year":"2017","journal-title":"J Nucl Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","article-title":"A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors","volume":"5","author":"Bomanji","year":"2009","journal-title":"J Nucl Med"},{"key":"19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40644-018-0136-x","article-title":"Changes in biodistribution onGa-DOTA-Octreotate PET\/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression","volume":"1","author":"Hofman","year":"2018","journal-title":"Cancer Imaging"},{"key":"20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2967\/jnumed.117.192203","article-title":"Long-Acting Somatostatin Analog Therapy Differentially AltersGa-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions","volume":"5","author":"Scott","year":"2018","journal-title":"J Nucl Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T12:36:55Z","timestamp":1597667815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":20,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2020,8,11]]}},"alternative-id":["27695"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27695","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]}}}